Log in

Denali Therapeutics News Headlines (NASDAQ:DNLI)

$14.40
-0.74 (-4.89 %)
(As of 10/18/2019 04:00 PM ET)
Today's Range
$14.24
Now: $14.40
$15.12
50-Day Range
$14.41
MA: $16.90
$19.59
52-Week Range
$13.78
Now: $14.40
$28.86
Volume272,401 shs
Average Volume358,255 shs
Market Capitalization$1.38 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.15

Headlines

Denali Therapeutics (NASDAQ DNLI) News Headlines

Source:
DateHeadline
Denali Therapeutics Inc (NASDAQ:DNLI) Given Average Rating of "Buy" by BrokeragesDenali Therapeutics Inc (NASDAQ:DNLI) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 4 at 3:59 AM
$10.86 Million in Sales Expected for Denali Therapeutics Inc (NASDAQ:DNLI) This Quarter$10.86 Million in Sales Expected for Denali Therapeutics Inc (NASDAQ:DNLI) This Quarter
www.americanbankingnews.com - October 3 at 10:21 AM
Denali Therapeutics Inc (NASDAQ:DNLI) Expected to Announce Earnings of -$0.51 Per ShareDenali Therapeutics Inc (NASDAQ:DNLI) Expected to Announce Earnings of -$0.51 Per Share
www.americanbankingnews.com - October 1 at 3:33 PM
Denali Therapeutics Inc to Post Q3 2019 Earnings of ($0.64) Per Share, Wedbush Forecasts (NASDAQ:DNLI)Denali Therapeutics Inc to Post Q3 2019 Earnings of ($0.64) Per Share, Wedbush Forecasts (NASDAQ:DNLI)
www.americanbankingnews.com - September 30 at 1:05 AM
Citi upgrades AbbVie in premarket analyst actionCiti upgrades AbbVie in premarket analyst action
seekingalpha.com - September 26 at 8:57 AM
Denali Therapeutics (NASDAQ:DNLI) Receives New Coverage from Analysts at WedbushDenali Therapeutics (NASDAQ:DNLI) Receives New Coverage from Analysts at Wedbush
www.americanbankingnews.com - September 25 at 8:46 PM
Leerink likes Acadia Pharma in premarket analyst actionLeerink likes Acadia Pharma in premarket analyst action
seekingalpha.com - September 13 at 8:52 AM
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s WebsiteDenali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinson’s Disease and Launch of Its Engage Parkinson’s Website
finance.yahoo.com - September 4 at 11:59 AM
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue EstimatesDenali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 6 at 11:22 PM
Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business HighlightsDenali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights
finance.yahoo.com - August 6 at 6:22 PM
Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 StudyDenali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study
finance.yahoo.com - August 5 at 9:23 AM
Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseDenali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
finance.yahoo.com - August 1 at 6:24 PM
Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company?Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company?
finance.yahoo.com - July 4 at 9:36 AM
DNLI Crosses Above Key Moving Average LevelDNLI Crosses Above Key Moving Average Level
www.nasdaq.com - June 20 at 6:09 PM
Denali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease PioneerDenali Therapeutics: Key Catalysts Coming Up For This Neurodegenerative Disease Pioneer
seekingalpha.com - June 12 at 12:44 PM
Denali's Hunter Syndrome Candidate Gets Orphan Drug StatusDenali's Hunter Syndrome Candidate Gets Orphan Drug Status
finance.yahoo.com - June 12 at 12:44 PM
Denalis DNL310 nabs accelerated review status in U.S. for MPS IIDenali's DNL310 nabs accelerated review status in U.S. for MPS II
seekingalpha.com - June 11 at 5:44 PM
Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement ProgramsDenali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs
finance.yahoo.com - June 11 at 10:22 AM
Notable Two Hundred Day Moving Average Cross - DNLINotable Two Hundred Day Moving Average Cross - DNLI
www.nasdaq.com - May 30 at 9:42 AM
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue EstimatesDenali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates
finance.yahoo.com - May 9 at 9:40 AM
Denali Therapeutics Reports First Quarter 2019 Financial ResultsDenali Therapeutics Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 8 at 6:26 PM
Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - May 3 at 6:13 PM
Controversial Alzheimer's Disease theory could pinpoint new drug targetsControversial Alzheimer's Disease theory could pinpoint new drug targets
finance.yahoo.com - May 1 at 6:12 PM
Here’s What Hedge Funds Think About Denali Therapeutics Inc. (DNLI)Here’s What Hedge Funds Think About Denali Therapeutics Inc. (DNLI)
finance.yahoo.com - April 30 at 5:52 PM
3 Biotech Stocks That Doubled After Hitting Bottom in 20183 Biotech Stocks That Doubled After Hitting Bottom in 2018
finance.yahoo.com - April 10 at 11:46 AM
Denali Therapeutics - On The MoveDenali Therapeutics - On The Move
www.finanznachrichten.de - April 4 at 9:45 AM
Did Denali Therapeutics's (NASDAQ:DNLI) Share Price Deserve to Gain 26%?Did Denali Therapeutics's (NASDAQ:DNLI) Share Price Deserve to Gain 26%?
finance.yahoo.com - April 2 at 5:51 PM
Interesting DNLI Put And Call Options For May 17thInteresting DNLI Put And Call Options For May 17th
www.nasdaq.com - March 21 at 6:10 PM
Denali Therapeutics Inc. (DNLI)Denali Therapeutics Inc. (DNLI)
finance.yahoo.com - March 14 at 10:04 AM
48 Stocks Moving In Wednesdays Mid-Day Session - Benzinga48 Stocks Moving In Wednesday's Mid-Day Session - Benzinga
www.benzinga.com - March 13 at 5:47 PM
Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates - NasdaqDenali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates - Nasdaq
www.nasdaq.com - March 12 at 10:34 PM
Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass EstimatesDenali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates
www.zacks.com - March 12 at 10:58 AM
Denali Therapeutics Reports Full Year 2018 Financial Results and Business HighlightsDenali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights
finance.yahoo.com - March 12 at 10:58 AM
Commit To Purchase Denali Therapeutics At $20, Earn 25.4% Annualized Using OptionsCommit To Purchase Denali Therapeutics At $20, Earn 25.4% Annualized Using Options
www.nasdaq.com - February 21 at 5:15 PM
Early-stage study of Denalis Alzheimers candidate DNL747 underway; shares up 1% premarketEarly-stage study of Denali's Alzheimer's candidate DNL747 underway; shares up 1% premarket
seekingalpha.com - February 15 at 10:12 AM
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s DiseaseDenali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease
finance.yahoo.com - February 15 at 10:12 AM
Sanofi delivers 2018 business EPS growth of 5.1% at CERSanofi delivers 2018 business EPS growth of 5.1% at CER
feeds.benzinga.com - February 7 at 2:47 AM
Genentech kills big drug study in early Alzheimers patientsGenentech kills big drug study in early Alzheimer's patients
www.bizjournals.com - January 30 at 5:40 PM
Denali Therapeutics IncDenali Therapeutics Inc
www.bloomberg.com - January 30 at 9:44 AM
Denali Therapeutics Inc.Denali Therapeutics Inc.
www.barrons.com - January 29 at 5:09 PM
Denali teams up with Sirion in gene therapiesDenali teams up with Sirion in gene therapies
seekingalpha.com - January 9 at 9:46 AM
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALSDenali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS
finance.yahoo.com - January 8 at 9:38 AM
Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s DiseaseDenali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinson’s Disease
finance.yahoo.com - December 10 at 9:22 AM
The Week Ahead In Biotech: Conferences, Clinical Trials And EarningsThe Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
finance.yahoo.com - December 8 at 4:26 PM
Commit To Buy Denali Therapeutics At $15, Earn 10.9% Annualized Using OptionsCommit To Buy Denali Therapeutics At $15, Earn 10.9% Annualized Using Options
www.nasdaq.com - November 21 at 4:24 PM
Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With SanofiDenali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi
finance.yahoo.com - November 20 at 9:17 AM
Denali Therapeutics Breaks Above 200-Day Moving Average - Bullish for DNLIDenali Therapeutics Breaks Above 200-Day Moving Average - Bullish for DNLI
www.nasdaq.com - November 15 at 4:24 PM
Benzingas Top Upgrades, Downgrades For November 15, 2018Benzinga's Top Upgrades, Downgrades For November 15, 2018
www.benzinga.com - November 15 at 9:22 AM
Form 3 Denali Therapeutics Inc. For: Nov 06 Filed by: Cook Jennifer E.Form 3 Denali Therapeutics Inc. For: Nov 06 Filed by: Cook Jennifer E.
www.streetinsider.com - November 10 at 9:30 AM
Denali Therapeutics (DNLI) Announces Jennifer Cook to BoardDenali Therapeutics (DNLI) Announces Jennifer Cook to Board
www.streetinsider.com - November 10 at 9:30 AM
This page was last updated on 10/19/2019 by MarketBeat.com Staff

Featured Article: Swap

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel